S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
Send us a text This conversation asks what impact Rezdiffra patient education might have on a U.S. healthcare system in which 38% of American adults live with some form of MASLD and 15% live with MASH. Louise Campbell starts off by saying she is “slightly fed up” with the idea that we cannot proceed too quickly for fear of overwhelming the system. Louise would rather flip focus to push systems to build the capacity they will need to handle the flow of patients that will certainly grow ...
24 Mars 202411min
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
Send us a text This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. To Wayne Eskridge, this “raises an entirely new field of education and outreach,” because now advocates can do more than merely be supportive emotionally. Advocates can, quoting again, “refresh our message and have broader perspectives and share a more hopeful outlook to the future” and talk about clinical trial participation and oth...
24 Mars 202411min
S5 - E7.3 - Patient advocacy and the Rezdiffra label
Send us a text This conversation focuses on the steps that patient advocates took to educate the FDA on what patients wanted in a MASH drug label, in this case for Rezdiffra. It starts with Jeff McIntyre reflecting on apparent changes in how the FDA thinks about labeling since the initial obeticholic acid Complete Response Letter in 2020. His specific point: since that first CRL, GLI has worked closely with patient advocates, including those on this call, to educate the FDA on what the...
23 Mars 202410min
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
Send us a text This conversation focuses on advocates' reactions throughout the day on Thursday, March 14, the day Rezdiffra became the first MASH drug approved in the U.S. Specifically, panelists discuss their thoughts and feelings as they reflected on Rezdiffra’s approval in the context of their personal experience. While no panelist is eligible to receive Rezdiffra as indicated, some thought back that day on their earlier patient experiences, while others thought of the patients for...
23 Mars 202413min
S5 - E7.2 - Identifying the target MASH patients for Rezdiffra
Send us a text This conversation focuses on two issues: (i) identifying the right target MASH patients for Rezdiffra, and (ii) the extensive Madrigal patient support program for Rezdiffra. It starts with Roger Green asking the group how the current set of target patients is defined. Jeff McIntyre points out that these are the patients currently treated for F2 or F3 MASH in the US healthcare system. Roger asks if this is analogous to the idea of “warehoused” patients observed in Hepatitis C. ...
23 Mars 20249min
S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future
Send us a text Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead. 00:00:00 - Surf's Up: Season 5 Episode 7 Opening introduction from an excited, enthusiastic panel, including brief quotes taken directly from the episode discussion. 00:05:55 - Groundbreakers Each panelist ...
21 Mars 20241h 5min
S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug
Send us a text As the conversation wound down, Roger Green offered panelists to address any issue pertaining to Rezdiffra, the first MASH drug, that had not come up in the hour-long conversation. The seven panelists raised eleven exceptionally diverse issues between them. Rather than provide a simple list of issues, the co-hosts invite you to listen to this short conversation to gain a fuller appreciation of each point.
19 Mars 20248min
S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch
Send us a text This conversation revolves around one question: "What lessons should the BioPharma industry take from the launch of Rezdiffra?" Answers revolve largely around clinical trial design and, generally, taking a broad, long-term view of what the trial must accomplish to optimize drug adoption. More specifically, Roger Green starts this conversation by noting that much of the SurfingMASH audience works in pharma or biotech. He asks what lessons they should take from this experience. ...
19 Mars 20247min
